Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2011

Open Access 01-12-2011 | Research

The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration

Authors: Janelle Drouin-Ouellet, Claire Gibrat, Mélanie Bousquet, Frédéric Calon, Jasna Kriz, Francesca Cicchetti

Published in: Journal of Neuroinflammation | Issue 1/2011

Login to get access

Abstract

Background

Mounting evidence supports a significant role of inflammation in Parkinson's disease (PD) pathophysiology, with several inflammatory pathways being suggested as playing a role in the dopaminergic degeneration seen in humans and animal models of the disease. These include tumor necrosis factor, prostaglandins and oxidative-related stress components. However, the role of innate immunity has not been established in PD.

Methods

Based on the fact that the myeloid differentiation primary response gene (88) (MyD88) is the most common adaptor protein implicated in toll-like receptor (TLR) signaling, critical in the innate immune response, we undertook a study to investigate the potential contribution of this specific pathway to MPTP-induced brain dopaminergic degeneration using MyD88 knock out mice (MyD88-/-), following our observations that the MyD88-dependent pathway was critical for MPTP dopaminergic toxicity in the enteric nervous system. Post-mortem analyses assessing nigrostriatal dopaminergic degeneration and inflammation were performed using HPLC, western blots, autoradiography and immunofluorescence.

Results

Our results demonstrate that MyD88-/- mice are as vulnerable to MPTP-induced dopamine and DOPAC striatal depletion as wild type mice. Furthermore, MyD88-/- mice show similar striatal dopamine transporter and tyrosine hydroxylase loss, as well as dopaminergic cell loss in the substantia nigra pars compacta in response to MPTP. To evaluate the extent of the inflammatory response created by the MPTP regimen utilized, we further performed bioluminescence imaging using TLR2-luc/gfp transgenic mice and microglial density analysis, which revealed a modest brain microglial response following MPTP. This was accompanied by a significant astrocytic reaction in the striatum, which was of similar magnitude both in wild type and MyD88-/- mice.

Conclusions

Our results suggest that subacute MPTP-induced dopaminergic degeneration observed in the central nervous system is MyD88-independent, in contrast to our recent observations that this pathway, in the same cohort of animals, is critical in the loss of dopaminergic neurons in the enteric nervous system.
Appendix
Available only for authorised users
Literature
1.
Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8: 382-397. 10.1016/S1474-4422(09)70062-6.CrossRefPubMed
2.
McGeer PL, McGeer EG: Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004, 1035: 104-116. 10.1196/annals.1332.007.CrossRefPubMed
3.
Banati RB, Daniel SE, Blunt SB: Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord. 1998, 13: 221-227. 10.1002/mds.870130205.CrossRefPubMed
4.
Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett. 1994, 172: 151-154. 10.1016/0304-3940(94)90684-X.CrossRefPubMed
5.
Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F: Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 1993, 52: 1-6. 10.1016/0306-4522(93)90175-F.CrossRefPubMed
6.
Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC: Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience. 1996, 72: 355-363. 10.1016/0306-4522(95)00578-1.CrossRefPubMed
7.
Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC: FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci. 1999, 19: 3440-3447.PubMed
8.
Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y: Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106: 518-526. 10.1007/s00401-003-0766-2.CrossRefPubMed
9.
Knott C, Stern G, Wilkin GP: Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci. 2000, 16: 724-739. 10.1006/mcne.2000.0914.CrossRefPubMed
10.
McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988, 38: 1285-1291.CrossRefPubMed
11.
Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T: Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett. 1995, 193: 129-132. 10.1016/0304-3940(95)11686-Q.CrossRefPubMed
12.
Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T: Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994, 180: 147-150. 10.1016/0304-3940(94)90508-8.CrossRefPubMed
13.
Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T: Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995, 9: 87-92. 10.1007/BF02252965.CrossRefPubMed
14.
Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T: Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm. 1996, 103: 1077-1081. 10.1007/BF01291792.CrossRefPubMed
15.
Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994, 165: 208-210. 10.1016/0304-3940(94)90746-3.CrossRefPubMed
16.
Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003, 60: 1059-1064. 10.1001/archneur.60.8.1059.CrossRefPubMed
17.
Hernan MA, Logroscino G, Garcia Rodriguez LA: Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology. 2006, 66: 1097-1099. 10.1212/01.wnl.0000204446.82823.28.CrossRefPubMed
18.
Ton TG, Heckbert SR, Longstreth WT, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H: Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord. 2006, 21: 964-969. 10.1002/mds.20856.CrossRefPubMed
19.
Akiyama H, McGeer PL: Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 1989, 489: 247-253. 10.1016/0006-8993(89)90857-3.CrossRefPubMed
20.
Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O: Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 2002, 15: 991-998. 10.1046/j.1460-9568.2002.01938.x.CrossRefPubMed
21.
Crotty S, Fitzgerald P, Tuohy E, Harris DM, Fisher A, Mandel A, Bolton AE, Sullivan AM, Nolan Y: Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease. Eur J Neurosci. 2008, 27: 294-300. 10.1111/j.1460-9568.2007.06018.x.CrossRefPubMed
22.
Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH: Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci. 2003, 18: 2731-2742. 10.1111/j.1460-9568.2003.03014.x.CrossRefPubMed
23.
Koprich JB, Reske-Nielsen C, Mithal P, Isacson O: Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008, 5: 8-10.1186/1742-2094-5-8.PubMedCentralCrossRefPubMed
24.
McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG: Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci. 2006, 26: 9365-9375. 10.1523/JNEUROSCI.1504-06.2006.PubMedCentralCrossRefPubMed
25.
He Y, Appel S, Le W: Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001, 909: 187-193. 10.1016/S0006-8993(01)02681-6.CrossRefPubMed
26.
Castano A, Herrera AJ, Cano J, Machado A: Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem. 1998, 70: 1584-1592.CrossRefPubMed
27.
Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem. 2002, 81: 1285-1297. 10.1046/j.1471-4159.2002.00928.x.CrossRefPubMed
28.
Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A: Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Immunopharmacology. 1998, 39: 167-180. 10.1016/S0162-3109(98)00022-8.CrossRefPubMed
29.
Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A: The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999, 156: 50-61. 10.1006/exnr.1998.6993.CrossRefPubMed
30.
Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. Faseb J. 2002, 16: 1474-1476.PubMed
31.
Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP: Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. Faseb J. 2006, 20: 670-682. 10.1096/fj.05-5106com.CrossRefPubMed
32.
Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999, 5: 1403-1409. 10.1038/70978.CrossRefPubMed
33.
Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA. 2003, 100: 5473-5478. 10.1073/pnas.0837397100.PubMedCentralCrossRefPubMed
34.
Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S: COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci. 2003, 991: 272-277.CrossRefPubMed
35.
Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA. 2003, 100: 6145-6150. 10.1073/pnas.0937239100.PubMedCentralCrossRefPubMed
36.
Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Zhang W, Hong JS, Liu B: Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. Faseb J. 2004, 18: 589-591.PubMed
37.
38.
Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD: The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br J Pharmacol. 1995, 114: 27-34.PubMedCentralCrossRefPubMed
39.
Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS: Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett. 2002, 329: 354-358. 10.1016/S0304-3940(02)00704-8.CrossRefPubMed
40.
Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G: Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation. 2006, 3: 6-10.1186/1742-2094-3-6.PubMedCentralCrossRefPubMed
41.
Needleman P, Isakson PC: The discovery and function of COX-2. J Rheumatol Suppl. 1997, 49: 6-8.PubMed
42.
Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801. 10.1016/j.cell.2006.02.015.CrossRefPubMed
43.
Hoffmann O, Braun JS, Becker D, Halle A, Freyer D, Dagand E, Lehnardt S, Weber JR: TLR2 mediates neuroinflammation and neuronal damage. J Immunol. 2007, 178: 6476-6481.CrossRefPubMed
44.
Kawai T, Akira S: Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci. 2008, 1143: 1-20. 10.1196/annals.1443.020.CrossRefPubMed
45.
Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, Krueger C, Nitsch R, Meisel A, Weber JR: Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol. 2007, 190: 28-33. 10.1016/j.jneuroim.2007.07.023.CrossRefPubMed
46.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007, 13: 1050-1059. 10.1038/nm1622.CrossRefPubMed
47.
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007, 13: 1042-1049. 10.1038/nm1638.CrossRefPubMed
48.
Janssens S, Beyaert R: A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci. 2002, 27: 474-482. 10.1016/S0968-0004(02)02145-X.CrossRefPubMed
49.
Dunne A, O'Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003, 2003: re3.PubMed
50.
Kang J, Rivest S: MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J Cell Biol. 2007, 179: 1219-1230. 10.1083/jcb.200705046.PubMedCentralCrossRefPubMed
51.
Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rube CE, Menger MD, Fassbender K: Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain. 2011, 134: 278-292. 10.1093/brain/awq325.CrossRefPubMed
52.
Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, Mitolo V, Nicolardi G: Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. Immunopharmacol Immunotoxicol. 2008, 30: 729-740. 10.1080/08923970802278557.CrossRefPubMed
53.
Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, et al: Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci USA. 2011, 108: 6632-6637. 10.1073/pnas.1017820108.PubMedCentralCrossRefPubMed
54.
Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK: Toll-Like Receptor 4 Promotes alpha-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. Am J Pathol. 2011, 179: 954-963. 10.1016/j.ajpath.2011.04.013.PubMedCentralCrossRefPubMed
55.
Cote M, Drouin-Ouellet J, Cicchetti F, Soulet D: The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity. Brain Behav Immun. 2011, 6: 1143-1152.CrossRef
56.
Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007, 2: 141-151.CrossRefPubMed
57.
Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G: The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000, 16: 135-142.PubMed
58.
Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M: The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem. 2001, 76: 1265-1274. 10.1046/j.1471-4159.2001.00183.x.CrossRefPubMed
59.
Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S: Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998, 9: 143-150. 10.1016/S1074-7613(00)80596-8.CrossRefPubMed
60.
Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999, 11: 115-122. 10.1016/S1074-7613(00)80086-2.CrossRefPubMed
61.
Gibrat C, Saint-Pierre M, Bousquet M, Levesque D, Rouillard C, Cicchetti F: Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem. 2009, 109: 1469-1482. 10.1111/j.1471-4159.2009.06072.x.CrossRefPubMed
62.
Lalancette-Hebert M, Phaneuf D, Soucy G, Weng YC, Kriz J: Live imaging of Toll-like receptor 2 response in cerebral ischaemia reveals a role of olfactory bulb microglia as modulators of inflammation. Brain. 2009, 132: 940-954.CrossRefPubMed
63.
Bousquet M, Gue K, Emond V, Julien P, Kang JX, Cicchetti F, Calon F: Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. J Lipid Res. 2011, 52: 263-271. 10.1194/jlr.M011692.PubMedCentralCrossRefPubMed
64.
Franklin KBJ, Paxinos G: The Mouse Brain in Stereotaxic Coordinates, Compact. 2008, Academic Press, 3
65.
Glaser JR, Glaser EM: Stereology, morphometry, and mapping: the whole is greater than the sum of its parts. J Chem Neuroanat. 2000, 20: 115-126. 10.1016/S0891-0618(00)00073-9.CrossRefPubMed
66.
Calon F, Lavertu N, Lemieux AM, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T: Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. Synapse. 2001, 40: 225-234. 10.1002/syn.1045.CrossRefPubMed
67.
Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC: Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem. 2002, 82: 615-624. 10.1046/j.1471-4159.2002.00990.x.CrossRefPubMed
68.
Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, Jackson-Lewis V, Vila M, Vonsattel JP, Heinecke JW, Przedborski S: Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci. 2005, 25: 6594-6600. 10.1523/JNEUROSCI.0970-05.2005.CrossRefPubMed
69.
Smith PF: Inflammation in Parkinson's disease: an update. Curr Opin Investig Drugs. 2008, 9: 478-484.PubMed
70.
Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al: Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009, 119: 182-192.PubMedCentralPubMed
71.
Liu B, Wang K, Gao HM, Mandavilli B, Wang JY, Hong JS: Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J Neurochem. 2001, 77: 182-189. 10.1046/j.1471-4159.2001.t01-1-00216.x.CrossRefPubMed
72.
Peterson JW, Bo L, Mork S, Chang A, Ransohoff RM, Trapp BD: VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J Neuropathol Exp Neurol. 2002, 61: 539-546.CrossRefPubMed
73.
Olson JK, Miller SD: Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004, 173: 3916-3924.CrossRefPubMed
74.
Furuya T, Hayakawa H, Yamada M, Yoshimi K, Hisahara S, Miura M, Mizuno Y, Mochizuki H: Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci. 2004, 24: 1865-1872. 10.1523/JNEUROSCI.3309-03.2004.CrossRefPubMed
75.
Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, Shimo-Nakanishi Y, Urabe T, Yamada M, Tamayose K, et al: An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA. 2001, 98: 10918-10923. 10.1073/pnas.191107398.PubMedCentralCrossRefPubMed
76.
Tatton NA, Kish SJ: In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 1997, 77: 1037-1048. 10.1016/S0306-4522(96)00545-3.CrossRefPubMed
77.
Kim NG, Lee H, Son E, Kwon OY, Park JY, Park JH, Cho GJ, Choi WS, Suk K: Hypoxic induction of caspase-11/caspase-1/interleukin-1beta in brain microglia. Brain Res Mol Brain Res. 2003, 114: 107-114.CrossRefPubMed
78.
Miller JA, Trout BR, Sullivan KA, Bialecki RA, Roberts RA, Tjalkens RB: Low-dose 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-kappaB reporter mice prior to loss of dopaminergic neurons. J Neurosci Res. 2011
79.
Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 2004, 4: 499-511. 10.1038/nri1391.CrossRefPubMed
80.
Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I: Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke. 2008, 39: 1314-1320. 10.1161/STROKEAHA.107.498212.CrossRefPubMed
Metadata
Title
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration
Authors
Janelle Drouin-Ouellet
Claire Gibrat
Mélanie Bousquet
Frédéric Calon
Jasna Kriz
Francesca Cicchetti
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2011
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-8-137

Other articles of this Issue 1/2011

Journal of Neuroinflammation 1/2011 Go to the issue

Research

In vivo imaging of lymphocytes in the CNS reveals different behaviour of naïve T cells in health and autoimmunity

Research

Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease

Research

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

Research

Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis

Research

The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide

Review

Toll-like receptors in cerebral ischemic inflammatory injury